All Releases
Ligand Earns $2.0 Million Milestone Payment as GlaxoSmithKline Begins Clinical Studies of Oral Drug for Thrombocytopenia
Jan 6, 2003
|
Ligand Earns $2.0 Million Milestone Payment as GlaxoSmithKline Begins Clinical Studies of Oral Drug for Thrombocytopenia
Dec 1, 2002
|
Ligand Earns $2.0 Million Milestone Payment as GlaxoSmithKline Begins Clinical Studies of Oral Drug for Thrombocytopenia
Dec 1, 2002
|
Ligand Earns $2.1 Million Milestone Payment as Lilly IND for LY674 Clears FDA
Nov 25, 2002
|
Ligand to Present at Salomon Smith Barney Global Health Care Conference
Oct 25, 2002
|
Ligand to Present at UBS Warburg Global Life Sciences Conference
Oct 8, 2002
|
Ligand Earns Two Milestones as Wyeth Advances Early-Stage Products for Women's Health
Sep 11, 2002
|
Targretin Increases Susceptibility of Leukemic B- and T-Cells to ONTAK, In Vitro Study of Ligand Products Published in the Journal Blood Demonstrates
Aug 29, 2002
|
Long-Term Study Presented at IASP Demonstrates AVINZA Once-Daily Provides Stable Analgesia for One Year Without Increase in Use of Rescue Medicines
Aug 19, 2002
|
Ligand Launches AVINZA , Once-Daily Treatment for Chronic, Moderate-to-Severe Pain
Jul 1, 2002
|
Ligand Earns $1.1 Million Milestone Payment as Lilly IND for LY929 Clears FDA
Jun 4, 2002
|
AVINZA Pharmacokinetic Study Published in Leading Pain Journal Demonstrates that<br>
New Drug has More Stable and Consistent PK Profile than MS Contin(R)
May 1, 2002
|
AVINZA Phase III Study Published in Leading Pain Journal Shows that New Drug Reduces Pain, Improves Sleep in Osteoarthritis Patients Compared to Placebo
May 1, 2002
|
Ligand Names Thomas H. Silberg Executive Vice President and Chief Operating Officer
Apr 22, 2002
|
ONTAK Phase III Study Published in March Issue of Clinical Lymphoma Shows Better Quality of Life for Responding CTCL Patients
Apr 18, 2002
|
Lilly, Ligand Extend R&D Collaboration To Discover And Develop Novel Drugs For Metabolic Diseases
Apr 12, 2002
|
FDA Approves AVINZA Once-Daily for Chronic, Moderate-to-Severe Pain
Mar 21, 2002
|
Targretin(R) Gel Achieved 86% Response Rate In Early-Stage CTCL Patients Treated For More Than One Year, Researchers Report At Aad Meeting
Feb 28, 2002
|
|
|
